Up to a quarter of operations performed in England are complicated with surgical site infections (SSIs), and whilst many resolve with simple treatment, some cause morbidity and major costs for the NHS. Minimising the risk of developing a SSI is therefore imperative. One area of controversy is the role of wound dressings, which are applied as standard practice following surgery in adults, but rarely in children. A systematic review of previous studies showed no evidence to suggest that using a dressing reduces the risk of SSIs, or that any particular dressing is more effective at reducing scarring, controlling pain or promoting patient acceptability. However, most studies were small and at high risk of bias, thus the evidence is of poor quality.
The Bluebelle Study is a NIHR Health Technology Assessment (HTA)-funded feasibility study being carried out in two parts.
Phase A (July 2014 to March 2016) includes: interviews with surgeons, nurses, midwives and adult patients to investigate current use of dressings and views about not using dressings; development of assessment measures for wounds and SSIs for use by clinicians and patients; observation of wound closure in theatre and literature reviews.
Phase B (February 2016 to October 2016), is a pilot randomised controlled trial (RCT), to establish whether it is possible to carry out a larger RCT in the future to compare the cost-effectiveness of simple dressings, tissue adhesive used as a dressing and no dressing to reduce SSIs following elective and unplanned surgery. Phase B will examine the overall acceptability of trial participation and delivery, and provide the opportunity to validate the measures developed in Phase A.
Professor Jane Blazeby, University of Bristol
Principal Investigator at University Hospitals Birmingham NHS Foundation Trust
Mr Thomas Pinkney
Principal Investigator at North Bristol NHS Trust
Mr Tim Draycott
Principal Investigator at University Hospitals Bristol NHS Foundation Trust
Mr Robert Longman
Study Coordinator and Primary Contact
Helen Talbot, Clinical Trials and Evaluation Unit, University of Bristol